Compare GOCO & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOCO | ITRM |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 24.3M |
| IPO Year | 2020 | 2018 |
| Metric | GOCO | ITRM |
|---|---|---|
| Price | $1.64 | $0.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.00 | ★ $9.00 |
| AVG Volume (30 Days) | 75.5K | ★ 1.0M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.82 | 57.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $798,894,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $947.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.74 | N/A |
| 52 Week Low | $1.31 | $0.14 |
| 52 Week High | $13.47 | $1.42 |
| Indicator | GOCO | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 48.30 | 39.42 |
| Support Level | N/A | $0.14 |
| Resistance Level | $2.53 | $0.39 |
| Average True Range (ATR) | 0.19 | 0.01 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 24.65 | 66.42 |
GoHealth Inc is a health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers' peace of mind when making healthcare decisions so consumers can focus on living life. It offers Medicare plans, including, but not limited to, Medicare Advantage, Medicare Supplement and prescription drug plans. Its proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer's specific needs.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.